Please use this identifier to cite or link to this item: https://swslhd.intersearch.com.au/swslhdjspui/handle/1/13179
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCiciriello, S.-
dc.contributor.authorLittlejohn, G.-
dc.contributor.authorTreuer, T.-
dc.contributor.authorGibson, K. A.-
dc.contributor.authorHaladyj, E.-
dc.contributor.authorYoussef, P.-
dc.contributor.authorBird, P.-
dc.contributor.authorO?Sullivan, C.-
dc.contributor.authorSmith, T.-
dc.contributor.authorDeakin, C. T.-
dc.date.accessioned2024-12-11T00:34:35Z-
dc.date.available2024-12-11T00:34:35Z-
dc.date.issued2024-
dc.identifier.issn0392856X (ISSN)-
dc.identifier.urihttps://swslhd.intersearch.com.au/swslhdjspui/handle/1/13179-
dc.description.abstractObjective To describe use and treatment persistence for Janus kinase inhibitors (JAKi) in rheumatoid arthritis (RA) by line of therapy, and the mechanism of action for the drug switched to after JAKi discontinuation. Methods This was a retrospective, observational analysis using the OPAL dataset, a large collection of deidentified electronic medical records from 112 rheumatologists around Australia. Adult patients with RA were included if they initiated tofacitinib (TOF), baricitinib (BARI) or upadacitinib (UPA) between 1 October 2015 and 30 September 2021. Data were summarised using descriptive statistics. Kaplan-Meier survival was used to analyse treatment persistence. Results 5,900 patients initiated JAKi within the study window (TOF n=3,662, BARI n=1,875, UPA n=1,814). Median persistence was similar across JAKi within each line of therapy where there was sufficient follow-up, and almost 3 years for first-line: 34.9 months (95% CI 30.8, 40.7; n=1,408) for TOF, 33.6 months (95% CI 25.7, not reached; n=545) for BARI. While JAKi to JAKi switching occurred across all lines of therapy, switches to a tumour necrosis factor inhibitor (TNFi) were more frequent after first- or second-line JAKi. JAKi monotherapy use at baseline increased with line of therapy, and was highest at follow-up after switching to another JAKi. ?Lack of efficacy? was the most common reason for discontinuing JAKi. Conclusion In this large analysis of Australian real-world practice separated by line of therapy, treatment persistence for JAKi was high overall subject to differential follow-up, but declined in later lines. JAKi to JAKi switching was observed across all lines of therapy. � Copyright CliniCal and ExpErimEntal rhEumatology 2024.-
dc.publisherClinical and Experimental Rheumatology S.A.S.-
dc.subjectb/tsDMARD JAK inhibitor rheumatoid arthritis treatment switching Adult Aged Antirheumatic Agents Arthritis, Rheumatoid Australia Azetidines Databases, Factual Drug Substitution Female Heterocyclic Compounds, 3-Ring Humans Janus Kinase Inhibitors Male Middle Aged Piperidines Practice Patterns, Physicians' Purines Pyrazoles Pyrimidines Retrospective Studies Sulfonamides Time Factors Treatment Outcome baricitinib C reactive protein hydroxychloroquine Janus kinase inhibitor leflunomide methotrexate salazosulfapyridine tofacitinib tumor necrosis factor inhibitor upadacitinib antirheumatic agent azetidine derivative fused heterocyclic rings piperidine derivative purine derivative pyrazole derivative pyrimidine derivative sulfonamide Article DAS28 disease activity follow up heart disease human hypertension ICD-10 information processing Kaplan Meier method kidney disease major clinical study sensitivity analysis venous thromboembolism clinical practice drug therapy factual database retrospective study time factor-
dc.titleReal-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL Dataset-
dc.typeJournal Article-
dc.description.affiliatesOPAL Rheumatology Ltd, Sydney, NSW, Australia Royal Melbourne Hospital, Melbourne, VIC, Australia Department of Medicine, Monash University, Clayton, VIC, Australia Eli Lilly and Company, Indianapolis, IN, United States Liverpool Hospital, Liverpool, NSW, Australia University of New South Wales, Kensington, NSW, Australia Royal Prince Alfred Hospital, Sydney, NSW, Australia University of Sydney, Sydney, NSW, Australia Centre for Adolescent Rheumatology Versus Arthritis, University College London, University College London Hospitals, Great Ormond Street Hospital, University College London, London, United Kingdom National Institute of Health Research Biomedical Centre, Great Ormond Street Hospital, London, United Kingdom-
dc.identifier.doi10.55563/clinexprheumatol/n0kjax-
dc.type.studyortrialArticle-
dc.identifier.journaltitleClinical and Experimental Rheumatology-
Appears in Collections:Liverpool Hospital

Files in This Item:
There are no files associated with this item.


Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing